![]() |
|
|
Vol. 27, Issue 1, 92-97, January 1999
Institute of Pharmaceutical Science, Hiroshima University School of
Medicine, Kasumi 1-2-3, Minami-ku, Hiroshima 734-8551, Japan
The results of this study show the quinone-dependent reduction of
tertiary amine N-oxides to the corresponding tertiary
amines by rat liver preparations. The reduction of imipramine
N-oxide to imipramine mediated by liver mitochondria,
microsomes, and cytosol proceeded in the presence of both NAD(P)H and
menadione under anaerobic conditions. When menadione was replaced with
1,4-naphthoquinone or 9,10-anthraquinone, similar results were obtained
in the cytosolic reduction. The quinone-dependent reducing activity in
liver cytosol was inhibited by dicumarol and carbon monoxide. This
result suggested that the activity is caused by DT-diaphorase, a
cytosolic quinone reductase, and hemoproteins in liver cytosol. In
fact, catalase and hemoglobin showed the ability to reduce imipramine
N-oxide when supplemented with DT-diaphorase. The
hemoproteins also exhibited the N-oxide reductase
activity with reduced menadione, menadiol. The N-oxide
reductase activity of the hemoproteins was also exhibited with
1,4-dihydroxynaphthalene, 1,4,9,10-tetrahydroxyanthracene, or
1,4-dihydroxy-9,10-anthraquinone. Furthermore, hematin revealed a
significant N-oxide-reducing activity in the presence of
menadiol. The reduction appears to proceed in two steps. The first step is reduction of menadione to menadiol by a quinone reductase with NADPH
or NADH. The second step is nonenzymatic reduction of tertiary amine
N-oxides to tertiary amines by menadiol, catalyzed by
the heme group of hemoproteins. Cyclobenzaprine N-oxide
and brucine N-oxide were also transformed similarly to
the corresponding amine by the quinone-dependent reducing system.
This article has been cited by other articles:
![]() |
B. Clement, S. Mau, S. Deters, and A. Havemeyer Drug Metab. Dispos., November 1, 2005; 33(11): 1740 - 1747. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Parte and D. Kupfer OXIDATION OF TAMOXIFEN BY HUMAN FLAVIN-CONTAINING MONOOXYGENASE (FMO) 1 AND FMO3 TO TAMOXIFEN-N-OXIDE AND ITS NOVEL REDUCTION BACK TO TAMOXIFEN BY HUMAN CYTOCHROMES P450 AND HEMOGLOBIN Drug Metab. Dispos., October 1, 2005; 33(10): 1446 - 1452. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Kulanthaivel, R. J. Barbuch, R. S. Davidson, P. Yi, G. A. Rener, E. L. Mattiuz, C. E. Hadden, L. A. Goodwin, and W. J. Ehlhardt SELECTIVE REDUCTION OF N-OXIDES TO AMINES: APPLICATION TO DRUG METABOLISM Drug Metab. Dispos., September 1, 2004; 32(9): 966 - 972. [Abstract] [Full Text] [PDF] |
||||